| Literature DB >> 22210172 |
Yan Zhang1, Fu-Geng Zhang, Chun Meng, Shou-Yuan Tian, Ya-Xin Wang, Wei Zhao, Jun Chen, Xiu-Shan Zhang, Yu Liang, Shi-Dong Zhang, Yan-Jie Xing.
Abstract
The volatile anesthetic sevoflurane is capable of inducing preconditioning and postconditioning effects in the brain. In this study, we investigated the effects of sevoflurane postconditioning on antioxidant and immunity indexes in cerebral ischemia reperfusion (CIR) rats. Rats were randomly assigned to five separate experimental groups I-V. In the sham group (I), rats were subjected to the same surgery procedures except for occlusion of the middle cerebral artery and exposed to 1.0 MAC sevoflurane 90 min after surgery for 30 min. IR control rats (group II) were subjected to middle cerebral artery occlusion (MCAO) for 90 min and exposed to O₂ for 30 min at the beginning of reperfusion. Sevoflurane 0.5, 1.0 and 1.5 groups (III, IV, V) were all subjected to MCAO for 90 min, but at the beginning of reperfusion exposed to 0.5 MAC, 1.0 MAC or 1.5 MAC sevoflurane for 30 min, respectively. Results showed that sevoflurane postconditioning can decrease serum tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), nitric oxide (NO), nitric oxide synthase (NOS) and increase serum interleukin-10 (IL-10) levels in cerebral ischemia reperfusion rats. In addition, sevoflurane postconditioning can still decrease blood lipid, malondialdehyde (MDA) levels, infarct volume and increase antioxidant enzymes activities, normal pyramidal neurons density in cerebral ischemia reperfusion rats. It can be concluded that sevoflurane postconditioning may decrease blood and brain oxidative injury and enhance immunity indexes in cerebral ischemia reperfusion rats.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22210172 PMCID: PMC6268413 DOI: 10.3390/molecules17010341
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Effects of sevoflurane postconditioning on serum TNF-α, IL-10 and IL-1β concentrations.
| Group | TNF-α (ng/mL) | IL-1β (ng/L) | IL-10 (ng/L) |
|---|---|---|---|
| I | 1.95 ± 0.11 | 10.65 ± 1.07 | 42.06 ± 3.08 |
| II | 4.65 ± 0.27 b | 19.66 ± 1.43 b | 21.52 ± 1.37 b |
| III | 3.06 ± 0.24 d | 17.03 ± 1.49 c | 29.29 ± 1.33 d |
| IV | 2.66 ± 0.29 d | 14.72 ± 1.35 d | 33.03 ± 1.97 d |
| V | 1.99 ± 0.2 d | 12.18 ± 1.22 d | 38.58 ± 1.85 d |
b p < 0.01, compared with group I; c p < 0.05, d p < 0.01, compared with group II.
Effects of sevoflurane postconditioning on serum NO and NOS concentrations.
| Group | NO (μmol/L) | NOS (U/mL) |
|---|---|---|
| I | 21.57 ± 2.07 | 22.18 ± 1.43 |
| II | 40.62 ± 2.31 b | 51.43 ± 0.96 b |
| III | 35.15 ± 1.99 c | 39.09 ± 1.37 d |
| IV | 29.07 ± 1.26 d | 29.04 ± 1.54 d |
| V | 21.36 ± 1.65 d | 20.13 ± 1.22 d |
b p < 0.01, compared with group I; c p < 0.05, d p < 0.01, compared with group II.
Effects of sevoflurane postconditioning on serum lipids levels.
| Group | TC (mmol/L) | TG (mmol/L) | HDL-c (mmol/L) | LDL-c (mmol/L) | LDL/HDL |
|---|---|---|---|---|---|
| I | 2.92 ± 0.2 | 0.74 ± 0.05 | 1.63 ± 0.12 | 1.02 ± 0.08 | 0.64 ± 0.04 |
| II | 5.84 ± 0.26 b | 2.03 ± 0.13 b | 0.72 ± 0.08 b | 5.21 ± 0.21 b | 7.09 ± 0.32 b |
| III | 5.17 ± 0.31 c | 1.75 ± 0.11 c | 1.03 ± 0.05 d | 4.52 ± 0.16 c | 4.37 ± 0.18 d |
| IV | 4.53 ± 0.19 d | 1.33 ± 0.09 d | 1.46 ± 0.08 d | 3.62 ± 0.18 d | 2.47 ± 0.13 d |
| V | 3.27 ± 0.22 d | 0.94 ± 0.07 d | 1.55 ± 0.09 d | 2.37 ± 0.11 d | 1.53 ± 0.09 d |
b p < 0.01, compared with group I; c p < 0.05, d p < 0.01, compared with group II.
Effects of sevoflurane postconditioning on serum and brain MDA, GSH concentrations.
| Group | MDA | GSH | ||
|---|---|---|---|---|
| Blood (nmol/mL) | Brain (nmol/g prot) | Blood (nmol/mL) | Brain (nmol/mg protein) | |
| I | 4.21 ± 0.21 | 3.15 ± 0.15 | 43.98 ± 3.08 | 58.32 ± 2.31 |
| II | 8.53 ± 0.37 b | 7.04 ± 0.43 b | 22.17 ± 1.43 b | 20.61 ± 1.26 b |
| III | 7.02 ± 0.42 c | 5.82 ± 0.22 d | 29.51 ± 1.24 d | 32.51 ± 1.32 d |
| IV | 5.97 ± 0.22 d | 5.01 ± 0.27 d | 35.66 ± 1.75 d | 41.28 ± 1.85 d |
| V | 4.88 ± 0.28 d | 4.22 ± 0.17 d | 40.71 ± 1.95 d | 59.03 ± 2.08 d |
b p < 0.01, compared with group I; c p < 0.05, d p < 0.01, compared with group II.
Effects of sevoflurane postconditioning on serum and brain SOD, CAT, GSH-Px and GR activities.
|
|
|
| ||
|
|
|
|
| |
| I | 276.5 ± 16.3 | 303.1 ± 22.9 | 39.11 ± 1.54 | 33.12 ± 1.84 |
| II | 132.1 ± 9.6 b | 137.4 ± 10.7 b | 15.03 ± 1.11 b | 12.84 ± 1.02 b |
| III | 176.4 ± 8.6 d | 199.2 ± 12.4 d | 19.99 ± 2.09 d | 21.87 ± 1.15 d |
| IV | 220.6 ± 11.6 d | 274.8 ± 17.3 d | 24.08 ± 1.57 d | 28.44 ± 1.36 d |
| V | 281.5 ± 20.5 d | 314.1 ± 19.2 d | 34.17 ± 1.72 d | 32.17 ± 1.83 d |
|
|
|
| ||
|
|
|
|
| |
| I | 52.19 ± 2.54 | 63.19 ± 2.98 | 29.07 ± 1.54 | 32.18 ± 1.76 |
| II | 22.15 ± 1.54 b | 27.51 ± 1.06 b | 12.16 ± 1.06 b | 15.27 ± 1.13 b |
| III | 32.97 ± 1.97 d | 37.82 ± 1.44 d | 19.03 ± 1.17 d | 21.54 ± 1.08 d |
| IV | 40.63 ± 2.61 d | 47.18 ± 2.31 d | 24.01 ± 1.32 d | 29.41 ± 1.57 d |
| V | 49.76 ± 2.88 d | 58.29 ± 2.28 d | 32.18 ± 1.69 d | 34.29 ± 1.39 d |
Values are given as mean ± SD from six rats in each group. b p < 0.01, compared with group I; d p < 0.01, compared with group II.
Figure 1Effect of sevoflurane postconditioning on normal pyramidal neurons density. b p < 0.01, compared with group I; d p < 0.01, compared with group II.
Figure 2Effect of sevoflurane postconditioning on infarct volume after ischemia-reperfusion. d p < 0.01, compared with group II.